Misleading high thyrotropin results obtained with a two-site immunometric assay involving a chimeric antibody.

the AxSYM, which showed an increase to 122%. From these data it is tempting to speculate that the Triton X-100 inactivation treatment could be useful for most commercial assays on high-throughput analyzers. However, it may well be that certain assays are more influenced by the presence of 1 mL/L Triton X-100 than others. These data suggest that it is possible to protect laboratory workers while offering essential analyses to the intensive or emergency care unit in case of a suspected viral infection with corona, Lassa, Ebola, or Marburg viruses. However, there are two limitations to the use of these inactivation procedures. The first limitation is that all of these procedures require that the transfer of plasma into the second tube and the inactivation procedure be performed by trained personnel in a biosafety level 2 safety cabinet under rigorous safety practices. The second limitation is that although there is evidence for an inactivation of these viruses by heat, there is evidence for effectiveness of Triton X-100 treatment only for the lipidenveloped HIV and Berne viruses (7, 8) and no published investigation of inactivation of the lipid-enveloped corona, Lassa, Ebola, or Marburg viruses. Nevertheless, the presented data can serve as a resource to estimate the effects on an analyte when one of these inactivation procedures is used as a safety measure to protect workers from lipid-enveloped viruses.